Aspen China and Veeva Host Digital Innovation Seminar at CIIE 2024: Powering a Healthier Future

On November 8, 2024, at the highly anticipated 2024 China International Import Expo (CIIE), Eisei China and Veeva Systems, a global leading provider of cloud solutions for the life sciences industry, successfully co-hosted a special session on digital innovation themed “New Digital Momentum, New Future for Health” at the Eisei China booth.

Mr. Larry Merizalde, CEO of Eisai China; Mr. Ding Xiaofeng, General Manager of Veeva China; Ms. Xie Kunrong, CFO and COO of Eisai China; and other members of the joint digital project co-creation teams from Eisai China and Veeva jointly attended the event.

Aisijian China’s next-generation Customer Relationship Management (CRM) system, built on the Veeva China CRM Suite, was successfully launched in just three months. This achievement has enabled digital-driven, efficient, and precise market decision-making and customer marketing, streamlined operational processes, empowered frontline business teams, and enhanced customer experience. Leveraging the efficient implementation, cost-control capabilities, and flexible scalability of the Veeva China Events Core project, Aisijian China successfully launched a new, modern meeting management platform within only five months. This platform has fully digitized the entire lifecycle of meeting management—including application, execution, and closure—significantly improving Aisijian’s operational efficiency and compliance. Furthermore, the platform provides data-driven deep insights for the business, helping Aisijian flexibly respond to complex compliance requirements and policy changes, thereby maintaining its leading position in a highly competitive market environment.

During the dialogue session, Mr. Larry Merizalde, CEO of Akeso China, and Mr. Ding Xiaofeng, General Manager of Veeva China, engaged in an in-depth discussion centered on three key themes. These themes covered: “Recent Developments in Akeso China’s Business,” “How Veeva Will Support Akeso China’s Growth in New Product Launches and Business Collaborations,” and “The Most Critical Support and Attributes Akeso China Expects from Veeva.” Additionally, both parties held detailed exchanges on “How Veeva Supports Akeso China’s Integration.”

Mr. Larry responded, “This year, Aspen China launched Endoquin, a drug for rare endocrine disorders. We also relaunched Mivacron, a neuromuscular blocking agent in the field of anesthesia, and signed a letter of intent with Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. to collaborate on liposomal bupivacaine injection for long-acting postoperative pain management. In December 2023, Aspen announced the acquisition of Sandoz’s China business. Moving forward, anesthesiology, antithrombotics, gastrointestinal disorders, and osteoporosis will become the company’s key therapeutic areas.”

“Leveraging mature platforms such as the Veeva China CRM Suite can streamline business processes and significantly enhance operational efficiency. Veeva’s OpenData solution offers extensive healthcare industry data, providing valuable benchmarking and insights that help align our strategy with best practices and maintain our competitiveness against other multinational corporations in the industry.”

Ms. Xie Kunrong, Chief Financial and Operating Officer of iSung China, stated, “Driven by data, iSung China has built a unified data platform over the past few years to integrate data from diverse sources. Leveraging Veeva’s localized product platform, we have established a new, fully localized system for iSung China. This ensures our operations remain legally compliant while digitally empowering our business. The launch of the new supply chain system enables us to respond more flexibly to market demands, optimize inventory management, and reduce operational costs. Looking ahead, we will continue to increase our investment in digital innovation, including the implementation of GxP-compliant systems.”

Mr. Hou Jianfeng, Senior IT Applications Manager at Ipsen China, stated, “Ipsen China’s CRM and Event platforms are both built on the Veeva China CRM Suite.”

Ding Shiqi, Deputy Director of Business Efficiency at Ipsen China; Shen Shanshan, Ethics and Compliance Officer at Ipsen China; Ma Junjie, Head of Commercial Consulting at Veeva China; and other members of the digital project co-creation team from Ipsen China and Veeva shared their successful experiences in building a next-generation Customer Relationship Management (CRM) system and a modern meeting management system.

Through this sharing session, iSung China not only successfully showcased its leading position and outstanding achievements in the field of digital innovation, but also further expanded its market influence and brand awareness. “Digital Intelligence Illuminates the Future, Joining Hands to Build a Healthy China.” Looking ahead, iSung China will continue to partner with Veeva to lead the future of digital innovation, upholding the principles of innovation, pragmatism, and efficiency, continuously promoting digital transformation and innovative development, and contributing greater wisdom and strength to the prosperity and growth of the healthcare industry.

As a multinational pharmaceutical company headquartered in Durban, South Africa, Aspen Pharmacare was founded in 1850 and boasts a rich history of 170 years, with operations spanning both emerging and mature markets. The Group maintains 69 offices worldwide and employs more than 9,100 people. It operates 23 manufacturing facilities across 15 countries and regions on six continents, delivering high-quality, patient-accessible medicines to over 115 countries and regions, with a commitment to improving patients’ health and well-being.

In 2015, Aspen Group established its first company in China. Following the acquisition of GlaxoSmithKline’s (GSK) antithrombotic drug portfolio and AstraZeneca’s (AZ) anesthesia drug portfolio, Aspen Group fully entered the Chinese market in 2017 with robust capabilities. Aspen China specializes in marketing, commercialization, and related services for anesthesia, antithrombotic, and endocrine drugs in mainland China, with business coverage extending to more than 3,000 hospitals across 31 provinces, municipalities, and autonomous regions nationwide. To safeguard the tangible interests of Chinese patients and contribute to achieving the “Healthy China 2030” goal, Aspen China is committed to sparing no effort in launching new products in the Chinese market.

Veeva is the global leader in cloud solutions for the life sciences industry, dedicated to innovation, product excellence, and customer success. Founded in 2007 and headquartered in the San Francisco Bay Area, Veeva currently employs more than 7,000 people worldwide. From large pharmaceutical companies to emerging biotechnology firms, Veeva serves over 1,000 life sciences customers globally. As a Public Benefit Corporation (PBC), Veeva is committed to helping the industries it serves enhance productivity and create high-quality jobs within our communities, while balancing the interests of all stakeholders, including customers, employees, society, and shareholders. Veeva entered the Chinese market in 2011, providing end-to-end cloud solutions that span the entire lifecycle of life sciences enterprises—from research and development and manufacturing to commercialization and marketing—with a commitment to building an industry-specific cloud for China’s life sciences sector.